Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 228

Results For "Act"

8006 News Found

ACG unveils patent-clean laminate ‘DryPod’ to shake up moisture-protection market
R&D | November 23, 2025

ACG unveils patent-clean laminate ‘DryPod’ to shake up moisture-protection market

The company says the innovation delivers stronger moisture protection for highly sensitive drug molecules


FDA approves combo therapy for Cisplatin-ineligible muscle-invasive bladder cancer patients
Drug Approval | November 23, 2025

FDA approves combo therapy for Cisplatin-ineligible muscle-invasive bladder cancer patients

The approvals target adult MIBC patients who are ineligible for cisplatin-based chemotherapy


Merck’s WINREVAIR shows promise in phase 2 study for hard-to-treat pulmonary hypertension
Clinical Trials | November 21, 2025

Merck’s WINREVAIR shows promise in phase 2 study for hard-to-treat pulmonary hypertension

The drug is being tested for combined post- and precapillary pulmonary hypertension due to heart failure with preserved ejection fraction


Merck KGaA fires up new supercomputer to turbocharge scientific breakthroughs
R&D | November 21, 2025

Merck KGaA fires up new supercomputer to turbocharge scientific breakthroughs

Exemplifies commitment of Merck to energy efficiency and sustainable practices in high-performance computing by featuring advanced water-cooling systems and a hybrid cloud infrastructure


Kiran Mazumdar-Shaw ranked 2nd most generous woman by Hurun India
People | November 21, 2025

Kiran Mazumdar-Shaw ranked 2nd most generous woman by Hurun India

The 2025 edition of the EdelGive Hurun list recognizes 24 exceptional women leaders for their philanthropic impact across critical areas


Piramal Pharma Solutions’ UK facility bags updated MHRA GMP certification
News | November 21, 2025

Piramal Pharma Solutions’ UK facility bags updated MHRA GMP certification

Grangemouth serves as PPS’s dedicated antibody-drug conjugate development and manufacturing hub


FDA grants accelerated approval to sevabertinib for non-squamous non-small cell lung cancer
Drug Approval | November 21, 2025

FDA grants accelerated approval to sevabertinib for non-squamous non-small cell lung cancer

HER2-mutant NSCLC typically has a poor prognosis and limited treatment options